**Author details**

Andrea Vila Domínguez, Manuel Enrique Jiménez Mejías and Younes Smani\* Institute of Biomedicine of Seville (IBiS), University Hospital Virgen del Rocío/CSIC/University of Seville, Seville, Spain

\*Address all correspondence to: ysmani-ibis@us.es

© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/ by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**111**

*Drugs Repurposing for Multi-Drug Resistant Bacterial Infections*

[8] Rampioni G, Visca P, Leoni L, Imperi F. Drug repurposing for antivirulence therapy against opportunistic bacterial pathogens. Emerging Topics in Life Sciences. 2017;**1**:13-23. DOI: 10.1042/

[9] Miró-Canturri A, Ayerbe-Algaba R, Smani Y. Drug repurposing for the treatment of bacterial and fungal infections. Frontiers in Microbiology.

[10] Theuretzbacher U, Outterson K, Engel A, Karlén A. The global

[11] Farha MA, Brown ED. Drug

[12] Swan GE. The pharmacology of halogenated salicylanilides and their anthelmintic use in animals. Journal of the South African Veterinary Association. 1999;**70**:61-70. DOI:

10.4102/jsava.v70i2.756

[13] Xu J, Pachón-Ibáñez ME, Cebrero-Cangueiro T, Chen H,

Sánchez-Céspedes J, Zhou J. Discovery of niclosamide and its O-alkylaminotethered derivatives as potent antibacterial agents against carbapenemase-producing and/or colistin resistant Enterobacteriaceae isolates. Bioorganic and Medicinal Chemistry Letters. 2019;**29**:1399-1402. DOI: 10.1016/j.bmcl.2019.03.032

[14] Costabile G, d'Angel I, Rampion G, Bondi R, Pompili B, Ascenzioni F, et al. Toward repositioning niclosamide for antivirulence therapy of Pseudomonas aeruginosa lung infections: Development of inhalable formulations through nanosuspension

preclinical antibacterial pipeline. Nature Reviews Microbiology. 2020;**18**(5):275- 285. DOI: 10.1038/s41579-019-0288-0

repurposing for antimicrobial discovery. Nature Microbiology. 2019;**4**:565-577

ETLS20160018

2019;**10**:41. DOI: 10.3389/

fmicb.2019.00041

*DOI: http://dx.doi.org/10.5772/intechopen.93635*

[1] Tacconelli E, Carrara E, Savoldi A, Harbarth S, Mendelson M, Monnet DL, et al. WHO pathogens priority list working group: Discovery, research, and development of new antibiotics: The WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infectious Diseases. 2018;**18**:318-327. DOI: 10.1016/S1473-3099(17)30753-3

**References**

[2] European Centre for Disease Prevention and Control. Surveillance of Antimicrobial Resistance in Europe

2018. Stockholm: ECDC; 2019

[3] Centers for Disease Control and Prevention (CDC). Antibiotic Resistance Threats in the United States, 2019. Atlanta, GA: U.S: Department of Health and Human Services, CDC; 2019

[4] Cassini A, Diaz Högberg L,

S1473-3099(18)30605-4

15 April 2020]

science.1176667

Plachouras D, Quattrocchi A, Hoxha A, Skov Simonsen G, et al. Attributable deaths and disability-adjusted lifeyears caused by infections with antibiotic-resistant bacteria in the EU and the European economic area in 2015: A population-level modelling analysis. Lancet Infectious Diseases. 2019;**19**:56-66. DOI: 10.1016/

[5] O'Neill J. Tackling Drug-Resistant Infections Globally: Final Report, and Recommendations The Review on Antimicrobial Resistance. 2016. Available from: https://amr-review.org/ sites/default/files/160525\_Final%20 paper\_with%20cover.pdf [Accessed:

[6] Fischbach MA, Walsh CT. Antibiotics

for emerging pathogens. Science. 2009;**325**:1089-1093. DOI: 10.1126/

[7] Brown D. Antibiotic resistance breakers: Can repurposed drugs fill the antibiotic discovery void? Nature Reviews Drug Discovery. 2015;**4**: 821-832. DOI: 10.1038/nrd4675

*Drugs Repurposing for Multi-Drug Resistant Bacterial Infections DOI: http://dx.doi.org/10.5772/intechopen.93635*
